Stay updated with breaking news from Multiple System Atrophy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage phar...
– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants...
– ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA – – Lead clinical development program enrolled 77 participants globally – MELBOURNE, Australia...
This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, second quarter...
Q3 2023 YUPELRI® net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1Progress made towards the achievement of non-GAAP profitability, with Q3...